S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Teva Pharmaceutical Industries (TEVA) Stock Forecast, Price & News

-0.03 (-0.39%)
(As of 05/16/2022 08:45 AM ET)
Today's Range
50-Day Range
52-Week Range
1,428 shs
Average Volume
8.92 million shs
Market Capitalization
$8.53 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Teva Pharmaceutical Industries logo

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Sales & Book Value

Annual Sales
$15.88 billion
Cash Flow
$3.66 per share
Book Value
$9.30 per share


Net Income
$417 million
Pretax Margin




Outstanding Shares
Free Float
Market Cap
$8.53 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.23 out of 5 stars

Medical Sector

229th out of 1,403 stocks

Pharmaceutical Preparations Industry

87th out of 667 stocks

Analyst Opinion: 3.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

Is Teva Pharmaceutical Industries a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Teva Pharmaceutical Industries stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View analyst ratings for Teva Pharmaceutical Industries
or view top-rated stocks.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Teva Pharmaceutical Industries

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) released its quarterly earnings data on Tuesday, May, 3rd. The company reported $0.55 EPS for the quarter, meeting analysts' consensus estimates of $0.55. The company earned $3.66 billion during the quarter, compared to analyst estimates of $3.75 billion. Teva Pharmaceutical Industries had a negative net margin of 3.95% and a positive trailing twelve-month return on equity of 24.04%. The company's revenue was down 8.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 EPS.
View Teva Pharmaceutical Industries' earnings history

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of $2.40-$2.60 for the period, compared to the consensus estimate of $2.51. The company issued revenue guidance of $15.40 billion-$16.00 billion, compared to the consensus revenue estimate of $15.97 billion.

What price target have analysts set for TEVA?

6 analysts have issued 12-month target prices for Teva Pharmaceutical Industries' stock. Their forecasts range from $7.00 to $14.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $11.20 in the next twelve months. This suggests a possible upside of 44.3% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries
or view top-rated stocks among Wall Street analysts.

Who are Teva Pharmaceutical Industries' key executives?
Teva Pharmaceutical Industries' management team includes the following people:
  • Mr. Kare Schultz, Pres, CEO & Director (Age 61, Pay $4.68M)
  • Mr. Eliyahu Sharon Kalif, Exec. VP & CFO (Age 49, Pay $1.74M)
  • Mr. Eric Drape, Exec. VP of Global Operations (Age 60, Pay $1.91M)
  • Mr. Mark Sabag, Exec. VP of International Markets Commercial (Age 51, Pay $1.79M) (LinkedIn Profile)
  • Dr. Sven Dethlefs Ph.D., Exec. VP of North America Commercial (Age 53, Pay $1.72M)
  • Mr. Amir Weiss, Sr. VP & Chief Accounting Officer (Age 45)
  • Mr. Kevin C. Mannix, Sr. VP of Investor Relations
  • Mr. David M. Stark, Exec. VP & Chief Legal Officer (Age 53)
  • Ms. Lori Queisser, Sr. VP & Global Compliance Officer
  • Ms. Galia Inbar, Exec. VP, Chief HR Officer and Head of Global Communications, Brand & ESG (Age 47)
What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries CEO Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among Teva Pharmaceutical Industries' employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.77%), Menora Mivtachim Holdings LTD. (2.11%), Migdal Insurance & Financial Holdings Ltd. (1.89%), Phoenix Holdings Ltd. (1.51%), Harel Insurance Investments & Financial Services Ltd. (0.95%) and Citigroup Inc. (0.00%). Company insiders that own Teva Pharmaceutical Industries stock include David Matthew Stark, Eli Shani, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends for Teva Pharmaceutical Industries

Which major investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., Citigroup Inc., Wolverine Asset Management LLC, JPMorgan Chase & Co., SG Americas Securities LLC, Blueshift Asset Management LLC, Northern Trust Corp, and Vontobel Holding Ltd.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include David Matthew Stark, Eli Shani, Eric Drape, Hafrun Fridriksdottir, Pharmaceutical Co Ltd Takeda, and Sven Dethlefs.
View insider buying and selling activity for Teva Pharmaceutical Industries
or view top insider-selling stocks.

Which major investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was bought by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Bank of Montreal Can, Allianz Asset Management GmbH, Renaissance Technologies LLC, Phoenix Holdings Ltd., BlackRock Inc., Dimensional Fund Advisors LP, and Meitav Dash Investments Ltd..
View insider buying and selling activity for Teva Pharmaceutical Industries
or or view top insider-buying stocks.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $7.76.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries has a market capitalization of $8.56 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($0.550010) on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

Teva Pharmaceutical Industries employs 37,537 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at (723) 914-8213, via email at [email protected], or via fax at 972-3923-4050.

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.